Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 5/20 | 0.49 |
| ▸ | MARK3 | P27448 | 4/20 | 0.49 |
| ▸ | MARK4 | Q96L34 | 4/20 | 0.49 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.49 |
| ▸ | SGK1 | O00141 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27788599 | 0.92 | MARK3 (0.44) | AURKBMARK3MARK4NUAK1PRKAA2 | |
| SCHEMBL27788598 | 0.87 | MARK3 (0.39) | AURKBMARK3MARK4NUAK1PRKAA2 | |
| SCHEMBL1355460 | 0.86 | MARK3 (0.52) | AURKBMARK3MARK4NUAK1PRKAA2 | |
| SCHEMBL1353985 | 0.85 | JAK2 (0.52) | AURKBMARK3MARK4NUAK1PRKAA2 | |
| SCHEMBL1355849 | 0.84 | AURKA (0.51) | AURKBMARK3MARK4NUAK1PRKAA2 | |
| SCHEMBL3587338 | 0.84 | MARK3 (0.42) | AURKBMARK3MARK4ABL1KIT | |
| SCHEMBL3576056 | 0.84 | MARK3 (0.42) | AURKBMARK3MARK4ABL1KIT | |
| SCHEMBL3585565 | 0.84 | MARK3 (0.42) | AURKBMARK3MARK4ABL1KIT | |
| SCHEMBL1353913 | 0.82 | MARK3 (0.41) | AURKBMARK3MARK4NUAK1PRKAA2 | |
| SCHEMBL3580795 | 0.81 | AURKA (0.63) | AURKBMARK3MARK4NUAK1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| CN-101616921-A | The 1-H-pyrazolo (3,4b) pyrimidine derivatives and as the purposes of mitotic kinase conditioning agent | BIOGEN IDEC INC | 2009-12-30 | — | — | CN | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
| CN-101616921-A | The 1-H-pyrazolo (3,4b) pyrimidine derivatives and as the purposes of mitotic kinase conditioning agent | BIOGEN IDEC INC | 2009-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | AURKB 8/4885MARK3 232/4885MARK4 251/4885 |
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | AURKB 6/4885MARK3 149/4885MARK4 181/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | AURKB 8/4885MARK3 232/4885MARK4 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.